ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$9.84
0.08 (0.82%)
▲
5d:
+3.91%
30d:
+17.56%
90d:
+16.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$22.15
Based on 13.7% avg growth
INTRINSIC VALUE TODAY
$13.76
28.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $9.84, which is considered extended relative to its 30-day fair value range of $8.55 to $9.67. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.0) compared to its historical average (12.0). Remarkably, the market is currently pricing in an annual earnings decline of 5.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is approaching resistance at $10.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADMA scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+72.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is approaching resistance at $10.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADMA scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+72.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.55 -
$9.67
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 72.8% below Wall St target ($17.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.55 -
$9.67
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.24
Resistance Level
$10.12
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.02
Wall Street Target
$17.00
(+72.8%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
33.0%
Valuation Discount vs History
-5.7% cheaper
PE vs Historical
10.0 vs 12.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.7%
(market-implied from PE analysis)
1-Year Target
$9.28
(-6%)
2-Year Target
$8.75
(-11%)
3-Year Target
$8.25
(-16%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$9.89
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 23.3%)
$36.98
(+276%)
Base:
(SPY PE: 10.0, Growth: 23.3%)
$18.45
(+88%)
Bear:
(PE: 8.5, Growth: 23.3%)
$15.69
(+59%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.94 | Current EPS (TTM): $0.70
Bull Case
$15.07
(+53%)
Analyst growth 40.4%, PE expands to 15.3
Base Case
$13.70
(+39%)
Market implied 40.4%, PE stable at 13.9
Bear Case
$6.64
(-33%)
Severe decline -20.0%, PE contracts to 11.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 12.0
Stabilization Target:
$11.79
(+19.8%)
PE Expansion Potential:
+19.8%
Share & Embed Analysis
Last updated: August 22, 2026 8:01 PM ET
Data refreshes hourly during market hours. Next update: 9:01 PM
Data refreshes hourly during market hours. Next update: 9:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
